Ellen
07-13-2010, 07:24 PM
http://www.financialpost.com/markets/news/Announces+Single+Injection+Insulin+Maintains+Tight +Glucose+Control+Days/3270737/story.html
BusinessWire ? Tuesday, Jul. 13, 2010
Extended Delivery Pharmaceuticals, LLC (EDP) announces that data regarding its lead development candidate SIA-II Insulin will be published in the new issue of Proceedings of the National Academy of Sciences of the USA. The manuscript describes multiple studies in vivo, in several species, demonstrating that a single injection of SIA-II maintains tight glucose control for over 140 days. SIA-II (Supramolecular insulin assembly -II) is a novel form of insulin.
?This may well be the single most important development in the management of diabetes during the last several years,? says James M. Fiore President and CEO of EDP.
SIA-II has been developed by the well-known glyco-biologist Professor Avadhesha Surolia, Director of the National Institute of Immunology in New Delhi, India (NII). Professor Surolia, who is the senior author of the manuscript said, ?My colleagues and I are thrilled at the un-expected physico-chemical properties of this novel form of insulin. We look forward to its clinical development for the benefit of science and advancement of medicine.?
The published manuscript lists a number of unique properties of SIA-II, which distinguish it from known forms of insulin. In addition to maintaining tight control over blood glucose levels, SIA-II was shown to prevent end organ damage, and no episodes of hypoglycemia were observed. Additional studies are scheduled to begin shortly in a prestigious academic diabetes center in the United States.
Extended Delivery Pharmaceuticals, www.extendeddelivery.com, holds a world-wide exclusive license to SIA-II, from the National Institute of Immunology in New Delhi, India (NII).
Contacts
Extended Delivery Pharmaceuticals
James M. Fiore, 203-656-2500
President & CEO
Read more: http://www.financialpost.com/markets/news/Announces+Single+Injection+Insulin+Maintains+Tight +Glucose+Control+Days/3270737/story.html#ixzz0tbzO7rkn
Abstract from PNAS
http://www.pnas.org/content/early/2010/06/15/1005704107.abstract
Supramolecular insulin assembly II for a sustained treatment of type 1 diabetes mellitus
Sarika Guptaa, Tandrika Chattopadhyaya, Mahendra Pal Singha, and Avadhesha Suroliaa,b,1
+ Author Affiliations
aNational Institute of Immunology, Aruna Asaf Ali Marg, New Delhi 110067, India; and
bMolecular Biophysics Unit, Indian Institute of Sciences, Bangalore 560012, India
Communicated by William J. Lennarz, State University of New York at Stony Brook, Stony Brook, NY, May 21, 2010 (received for review May 1, 2009)
Abstract
Diabetes is a chronic disease requiring continuous medical supervision and patient education to prevent acute secondary complications. In this study, we have harnessed the inherent property of insulin to aggregate into an oligomeric intermediate on the pathway to amyloid formation, to generate a form that exhibits controlled and sustained release for extended periods. Administration of a single dose of the insulin oligomer, defined here as the supramolecular insulin assembly II (SIA-II), to experimental animals rendered diabetic by streptozotocin or alloxan, released the hormone capable of maintaining physiologic glucose levels for > 120 days for bovine and > 140 days for recombinant human insulin without fasting hypoglycemia. Moreover, the novel SIA-II described here not only improved the glycemic control, but also reduced the extent of secondary diabetic complications.
protein folding hyperglycemia normoglycemia insulin-like growth factor-1
Footnotes
1To whom correspondence should be addressed. E-mail: surolia@nii.res.in.
Author contributions: S.G. and A.S. designed research; S.G., T.C., and M.P.S. performed research; S.G., T.C., M.P.S., and A.S. analyzed data; and S.G., T.C., and A.S. wrote the paper.
The authors declare no conflict of interest.
This article contains supporting information online at www.pnas.org/lookup/suppl/doi:10.1073/pnas.1005704107/-/DCSupplemental.
BusinessWire ? Tuesday, Jul. 13, 2010
Extended Delivery Pharmaceuticals, LLC (EDP) announces that data regarding its lead development candidate SIA-II Insulin will be published in the new issue of Proceedings of the National Academy of Sciences of the USA. The manuscript describes multiple studies in vivo, in several species, demonstrating that a single injection of SIA-II maintains tight glucose control for over 140 days. SIA-II (Supramolecular insulin assembly -II) is a novel form of insulin.
?This may well be the single most important development in the management of diabetes during the last several years,? says James M. Fiore President and CEO of EDP.
SIA-II has been developed by the well-known glyco-biologist Professor Avadhesha Surolia, Director of the National Institute of Immunology in New Delhi, India (NII). Professor Surolia, who is the senior author of the manuscript said, ?My colleagues and I are thrilled at the un-expected physico-chemical properties of this novel form of insulin. We look forward to its clinical development for the benefit of science and advancement of medicine.?
The published manuscript lists a number of unique properties of SIA-II, which distinguish it from known forms of insulin. In addition to maintaining tight control over blood glucose levels, SIA-II was shown to prevent end organ damage, and no episodes of hypoglycemia were observed. Additional studies are scheduled to begin shortly in a prestigious academic diabetes center in the United States.
Extended Delivery Pharmaceuticals, www.extendeddelivery.com, holds a world-wide exclusive license to SIA-II, from the National Institute of Immunology in New Delhi, India (NII).
Contacts
Extended Delivery Pharmaceuticals
James M. Fiore, 203-656-2500
President & CEO
Read more: http://www.financialpost.com/markets/news/Announces+Single+Injection+Insulin+Maintains+Tight +Glucose+Control+Days/3270737/story.html#ixzz0tbzO7rkn
Abstract from PNAS
http://www.pnas.org/content/early/2010/06/15/1005704107.abstract
Supramolecular insulin assembly II for a sustained treatment of type 1 diabetes mellitus
Sarika Guptaa, Tandrika Chattopadhyaya, Mahendra Pal Singha, and Avadhesha Suroliaa,b,1
+ Author Affiliations
aNational Institute of Immunology, Aruna Asaf Ali Marg, New Delhi 110067, India; and
bMolecular Biophysics Unit, Indian Institute of Sciences, Bangalore 560012, India
Communicated by William J. Lennarz, State University of New York at Stony Brook, Stony Brook, NY, May 21, 2010 (received for review May 1, 2009)
Abstract
Diabetes is a chronic disease requiring continuous medical supervision and patient education to prevent acute secondary complications. In this study, we have harnessed the inherent property of insulin to aggregate into an oligomeric intermediate on the pathway to amyloid formation, to generate a form that exhibits controlled and sustained release for extended periods. Administration of a single dose of the insulin oligomer, defined here as the supramolecular insulin assembly II (SIA-II), to experimental animals rendered diabetic by streptozotocin or alloxan, released the hormone capable of maintaining physiologic glucose levels for > 120 days for bovine and > 140 days for recombinant human insulin without fasting hypoglycemia. Moreover, the novel SIA-II described here not only improved the glycemic control, but also reduced the extent of secondary diabetic complications.
protein folding hyperglycemia normoglycemia insulin-like growth factor-1
Footnotes
1To whom correspondence should be addressed. E-mail: surolia@nii.res.in.
Author contributions: S.G. and A.S. designed research; S.G., T.C., and M.P.S. performed research; S.G., T.C., M.P.S., and A.S. analyzed data; and S.G., T.C., and A.S. wrote the paper.
The authors declare no conflict of interest.
This article contains supporting information online at www.pnas.org/lookup/suppl/doi:10.1073/pnas.1005704107/-/DCSupplemental.